ECT/Succinylcholine: Biochemical, Serum and Cardiovascular Changes

This study has suspended participant recruitment.
(Study on hold since 2009. Awaiting FDA approval of Sugammdex to complete second arm of study.)
Sponsor:
Information provided by (Responsible Party):
University of California, San Francisco
ClinicalTrials.gov Identifier:
NCT00750906
First received: September 9, 2008
Last updated: March 6, 2013
Last verified: March 2013
  Purpose

This study will be conducted to determine the pharmacodynamics, cardiovascular and biochemical effects of succinylcholine when given during electroconvulsive therapy. (ECT). This is a single center, prospective, study in patients who will be receiving ECT as indicated and prescribed by their psychiatrist. The study will be performed twice on each patient, 48-72 hours apart during consecutively scheduled ECT procedures.


Condition
Depression

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: The Muscle Biochemical, Serum Potassium and Cardiovascular Changes After Succinylcholine in Patients Undergoing Electroconvulsive Therapy.

Resource links provided by NLM:


Further study details as provided by University of California, San Francisco:

Estimated Enrollment: 20
Study Start Date: October 2008
Detailed Description:

Patients will receive the anesthetic that is traditionally given which includes appropriate doses of succinylcholine. Serum potassium and creatinine phosphokinase (CK) levels will be determined pre and post anesthesia; serum and urine myoglobin will be determined post anesthesia. Vital signs data [i.e., heart rate (arrhythmias) and arterial blood pressure] will be compared pre and post anesthesia. In addition patients will be asked about the presence of muscle pain (myalgia) 1 hour before discharge from the recovery room and the following day post ECT.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients undergoing electroconvulsive therapy.

Criteria

Inclusion Criteria:

  1. A male or non-pregnant female aged 18 years and older
  2. American Society of Anesthesiologists physical status 1, 2, 3
  3. Scheduled to undergo electroconvulsive therapy under general anesthesia
  4. Have given written informed consent

Exclusion Criteria:

  1. Pregnant or nursing
  2. Any patient in the study investigators opinion who may not be suitable for research.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00750906

Locations
United States, California
University of California San Francisco
San Francisco, California, United States, 94143
Sponsors and Collaborators
University of California, San Francisco
Investigators
Study Director: Ronald D Miller, MD University of California, San Francisco
  More Information

No publications provided

Responsible Party: University of California, San Francisco
ClinicalTrials.gov Identifier: NCT00750906     History of Changes
Other Study ID Numbers: H898-32701
Study First Received: September 9, 2008
Last Updated: March 6, 2013
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Depression
Depressive Disorder
Behavioral Symptoms
Mood Disorders
Mental Disorders
Succinylcholine
Neuromuscular Depolarizing Agents
Neuromuscular Blocking Agents
Neuromuscular Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 17, 2014